IART Projected Dividend Yield

Integra LifeSciences Holdings Corp ( NASDAQ : IART )

Integra LifeSciences Holdings is engaged in medical technology. Co.'s global reportable business segments include: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment focuses on the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Tissue Technologies segment has a regenerative platform that primarily addresses the needs of plastic, reconstructive and general surgeons focused on the treatment of acute wounds, such as burns, chronic wounds, including diabetic foot ulcers, and surgical tissue repair, such as hernia, tendon, peripheral nerve repair and protection.

20 YEAR PERFORMANCE RESULTS